News

Patent license agreement with KRICT

관리자 │ 2023-05-19

HIT

523

Aevisbio and KRICT signed the patent licensing agreement in connection with low-molecular compounds having celeblon-binding activity and their applications. 


Previous Post Chemical Research Center founded at Institut Pasteur Korea, Pan-gyo, Korea
Next Post The 6th Target Protein Dissolution Summit